Melvin Booth - Catalent Director
| CTLT Stock | USD 55.92 0.12 0.22% |
Director
Mr. Melvin D. Booth Ph.D, CPA, is Independent Director of the Company. Mr. Booth was a director since August 2014 and was a member of the board of directors of our subsidiary, Catalent Pharma Solutions, Inc., from July 2010 until September 2014. Most recently, Mr. Booth served as President and Chief Operating Officer of Medimmune, Inc. from 1998 through his retirement in 2003, and as a member of its board of directors from 1998 through 2005. Prior to that, Mr. Booth was President, Chief Operating Officer and Director of Human Genome Sciences, Inc. from 1995 to 1998. Mr. Booth also served in a variety of senior leadership positions for Syntex Inc., including leading both Syntex Laboratories, Inc. and Syntex Pharmaceuticals Pacific. Mr. Booth also served as Lead Director for Millipore Corporation until its acquisition by Merck KGaA and Chairman of the Board for eResearch Technology, Inc. until its sale in May 2016. Mr. Booth currently serves as Chairman of the Board for Mallinckrodt plc and as a strategic advisor in life sciences for Genstar Capital since 2010.
| Age | 73 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Larry Bird | PetIQ Inc | 63 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Scott Huff | PetIQ Inc | 46 | |
| James Clarke | PetIQ Inc | 45 | |
| Will Santana | PetIQ Inc | 45 | |
| Mark First | PetIQ Inc | 53 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Susan Sholtis | PetIQ Inc | 51 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
| Gary Michael | PetIQ Inc | 77 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0075 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, CFO and Executive VP | ||
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Bruce McEvoy, Director | ||
| Aris Gennadios, President - Softgel Technologies | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| James Quella, Director | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Gregory Lucier, Independent Director | ||
| Scott Houlton, President - Development and Clinical Services | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Matti Masanovich, Senior CFO | ||
| Martin Carroll, Director | ||
| Julien Meissonnier, VP Officer | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Lance Miyamoto, Senior Vice President - Human Resources | ||
| Rosemary Crane, Independent Director | ||
| Sharon Johnson, Sr. VP of Quality, Product Devel., and Regulatory Affairs | ||
| Joseph JD, General VP | ||
| Peter Zippelius, Independent Director | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Stephen Leonard, Sr. VP of Global Operations | ||
| Chinh Chu, Chairman of the Board | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Christine Dolan, Senior Vice President - Product Development | ||
| Christa Kreuzburg, Independent Director | ||
| William Downie, Sr. VP of Global Marketing and Sales | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Lucier Gregory, Director | ||
| Barry Littlejohns, President - Advanced Delivery Technologies | ||
| Melvin Booth, Director | ||
| Jack Stahl, Lead Independent Director | ||
| Uwe Rohrhoff, Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0075 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 14.89 B | ||||
| Shares Outstanding | 180.97 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 7.19 M | ||||
| Price To Earning | 17.80 X | ||||
| Price To Book | 2.76 X |
Pair Trading with Catalent
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalent position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalent will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Catalent could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalent when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalent - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalent to buy it.
The correlation of Catalent is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalent moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalent moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalent can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Catalent Stock analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.15) | Earnings Share (7.18) | Revenue Per Share 22.579 | Quarterly Revenue Growth (0.11) | Return On Assets (0.01) |
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.